PMID- 32760274
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20240329
IS  - 1663-9812 (Print)
IS  - 1663-9812 (Electronic)
IS  - 1663-9812 (Linking)
VI  - 11
DP  - 2020
TI  - Jieduquyuziyin Prescription Suppresses Inflammatory Activity of MRL/lpr Mice and 
      Their Bone Marrow-Derived Macrophages via Inhibiting Expression of IRAK1-NF-kappaB 
      Signaling Pathway.
PG  - 1049
LID - 10.3389/fphar.2020.01049 [doi]
LID - 1049
AB  - Jieduquyuziyin prescription (JP) has been used to treat systemic lupus 
      erythematosus (SLE). Although the effectiveness of JP in the treatment of SLE has 
      been clinically proven, the underlying mechanisms have yet to be completely 
      understood. We observed the therapeutic actions of JP in MRL/lpr mice and their 
      bone marrow-derived macrophages (BMDMs) and the potential mechanism of their 
      inhibition of inflammatory activity. To estimate the effect of JP on suppressing 
      inflammatory activity, BMDMs of MRL/lpr and MRL/MP mice were treated with 
      JP-treated serum, and MRL/lpr mice were treated by JP for 8 weeks. Among them, JP 
      and its treated serum were subjected to quality control, and BMDMs were separated 
      and identified. The results showed that in the JP group of BMDMs stimulated by 
      Lipopolysaccharide (LPS) in MRL/lpr mice, the secretion of interleukin-6 (IL-6) 
      and tumor necrosis factor-alpha (TNF-alpha) reduced, and the expressions of Interleukin-1 
      receptor-associated kinase 1 (IRAK1) and its downstream nuclear factor kappaB (NF-kappaB) 
      pathway decreased. Meanwhile, the alleviation of renal pathological damage, the 
      decrease of urinary protein and serum anti-dsDNA contents, the inhibition of 
      TNF-alpha level, and then the suppression of the IRAK1-NF-kappaB inflammatory signaling 
      in the spleen and kidney, confirmed that the therapeutic effect of JP. These 
      results demonstrated that JP could inhibit the inflammatory activity of MRL/lpr 
      mice and their BMDMs by suppressing the activation of IRAK1-NF-kappaB signaling and 
      was supposed to be a good choice for the treatment of SLE.
CI  - Copyright (c) 2020 Ji, Fan, Hou, Fu, Bao, Zhuang, Chen, Fan and Li.
FAU - Ji, Lina
AU  - Ji L
AD  - The First College of Clinical Medicine, Zhejiang Chinese Medical University, 
      Hangzhou, China.
FAU - Fan, Xuemin
AU  - Fan X
AD  - School of Basic Medical Sciences, Zhejiang Chinese Medical University, Hangzhou, 
      China.
FAU - Hou, Xiaoli
AU  - Hou X
AD  - Academy of Chinese Medical Science, Zhejiang Chinese Medical University, 
      Hangzhou, China.
FAU - Fu, Danqing
AU  - Fu D
AD  - School of Basic Medical Sciences, Zhejiang Chinese Medical University, Hangzhou, 
      China.
FAU - Bao, Jie
AU  - Bao J
AD  - School of Basic Medical Sciences, Zhejiang Chinese Medical University, Hangzhou, 
      China.
FAU - Zhuang, Aiwen
AU  - Zhuang A
AD  - Institute of TCM Literature and Information, Zhejiang Academy of Traditional 
      Chinese Medicine, Hangzhou, China.
FAU - Chen, Sixiang
AU  - Chen S
AD  - The Second College of Clinical Medicine, Zhejiang Chinese Medical University, 
      Hangzhou, China.
FAU - Fan, Yongsheng
AU  - Fan Y
AD  - The First College of Clinical Medicine, Zhejiang Chinese Medical University, 
      Hangzhou, China.
FAU - Li, Rongqun
AU  - Li R
AD  - School of Basic Medical Sciences, Zhejiang Chinese Medical University, Hangzhou, 
      China.
LA  - eng
PT  - Journal Article
DEP - 20200714
PL  - Switzerland
TA  - Front Pharmacol
JT  - Frontiers in pharmacology
JID - 101548923
PMC - PMC7372094
OTO - NOTNLM
OT  - IRAK1-NF-kappaB signalling
OT  - Jieduquyuziyin prescription
OT  - MRL/lpr mice
OT  - bone marrow-derived macrophages
OT  - inflammatory activity
OT  - systemic lupus erythematosus
EDAT- 2020/08/08 06:00
MHDA- 2020/08/08 06:01
PMCR- 2020/07/14
CRDT- 2020/08/08 06:00
PHST- 2020/03/18 00:00 [received]
PHST- 2020/06/26 00:00 [accepted]
PHST- 2020/08/08 06:00 [entrez]
PHST- 2020/08/08 06:00 [pubmed]
PHST- 2020/08/08 06:01 [medline]
PHST- 2020/07/14 00:00 [pmc-release]
AID - 10.3389/fphar.2020.01049 [doi]
PST - epublish
SO  - Front Pharmacol. 2020 Jul 14;11:1049. doi: 10.3389/fphar.2020.01049. eCollection 
      2020.